Cargando…

In Silico Discovery of Candidate Drugs against Covid-19

Previous studies reported that Angiotensin converting enzyme 2 (ACE2) is the main cell receptor of SARS-CoV and SARS-CoV-2. It plays a key role in the access of the virus into the cell to produce the final infection. In the present study we investigated in silico the basic mechanism of ACE2 in the l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cava, Claudia, Bertoli, Gloria, Castiglioni, Isabella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232366/ https://www.ncbi.nlm.nih.gov/pubmed/32268515 http://dx.doi.org/10.3390/v12040404

Ejemplares similares

Potential drugs against COVID-19 revealed by gene expression profile, molecular docking and molecular dynamic simulation
por: Cava, Claudia, et al.
Publicado: (2021)

In silico identification of drug target pathways in breast cancer subtypes using pathway cross-talk inhibition
por: Cava, Claudia, et al.
Publicado: (2018)

In Silico Approach for the Definition of radiomiRNomic Signatures for Breast Cancer Differential Diagnosis
por: Gallivanone, Francesca, et al.
Publicado: (2019)

A protein interaction map identifies existing drugs targeting SARS-CoV-2
por: Cava, Claudia, et al.
Publicado: (2020)

In-Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer
por: Cava, Claudia, et al.
Publicado: (2018)

Portrait of Tissue-Specific Coexpression Networks of Noncoding RNAs (miRNA and lncRNA) and mRNAs in Normal Tissues
por: Cava, Claudia, et al.
Publicado: (2019)

MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer
por: Bertoli, Gloria, et al.
Publicado: (2015)

MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer
por: Bertoli, Gloria, et al.
Publicado: (2016)

Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential
por: Cava, Claudia, et al.
Publicado: (2015)

Triple negative aggressive phenotype controlled by miR-135b and miR-365: new theranostics candidates
por: Bertoli, Gloria, et al.
Publicado: (2021)

Minor Allele Frequencies and Molecular Pathways Differences for SNPs Associated with Amyotrophic Lateral Sclerosis in Subjects Participating in the UKBB and 1000 Genomes Project
por: D’Antona, Salvatore, et al.
Publicado: (2021)

In Silico Identification of miRNA–lncRNA Interactions in Male Reproductive Disorder Associated with COVID-19 Infection
por: Sabetian, Soudabeh, et al.
Publicado: (2021)

Potential Role of miRNAs as Theranostic Biomarkers of Epilepsy
por: Cava, Claudia, et al.
Publicado: (2018)

Integrative Analysis with Monte Carlo Cross-Validation Reveals miRNAs Regulating Pathways Cross-Talk in Aggressive Breast Cancer
por: Colaprico, Antonio, et al.
Publicado: (2015)

In silico identification of drug candidates against COVID-19
por: Wu, Yifei, et al.
Publicado: (2020)

Identification of key miRNAs in prostate cancer progression based on miRNA-mRNA network construction
por: Santo, Giulia Dal, et al.
Publicado: (2022)

Integration of multiple networks and pathways identifies cancer driver genes in pan-cancer analysis
por: Cava, Claudia, et al.
Publicado: (2018)

How interacting pathways are regulated by miRNAs in breast cancer subtypes
por: Cava, Claudia, et al.
Publicado: (2016)

MicroRNA-567 dysregulation contributes to carcinogenesis of breast cancer, targeting tumor cell proliferation, and migration
por: Bertoli, Gloria, et al.
Publicado: (2016)

Circulating microRNAs as Potential Novel Diagnostic Biomarkers to Predict Drug Resistance in Temporal Lobe Epilepsy: A Pilot Study
por: De Benedittis, Selene, et al.
Publicado: (2021)

Identification of microRNA clusters cooperatively acting on epithelial to mesenchymal transition in triple negative breast cancer
por: Cantini, Laura, et al.
Publicado: (2019)

Integration of mRNA Expression Profile, Copy Number Alterations, and microRNA Expression Levels in Breast Cancer to Improve Grade Definition
por: Cava, Claudia, et al.
Publicado: (2014)

Multi-Step In Silico Discovery of Natural Drugs against COVID-19 Targeting Main Protease
por: Elkaeed, Eslam B., et al.
Publicado: (2022)

Patient-Specific Network for Personalized Breast Cancer Therapy with Multi-Omics Data
por: Cava, Claudia, et al.
Publicado: (2021)

SpidermiR: An R/Bioconductor Package for Integrative Analysis with miRNA Data
por: Cava, Claudia, et al.
Publicado: (2017)

Indole alkaloids as potential candidates against COVID-19: an in silico study
por: Mohseni, Mehran, et al.
Publicado: (2022)

Deep Learning Approach for Discovery of In Silico Drugs for Combating COVID-19
por: Jha, Nishant, et al.
Publicado: (2021)

Theranostic application of miR-429 in HER2+ breast cancer
por: Cava, Claudia, et al.
Publicado: (2020)

Identification of Breast Cancer Subtype-Specific Biomarkers by Integrating Copy Number Alterations and Gene Expression Profiles
por: Cava, Claudia, et al.
Publicado: (2021)

In Silico Models for Anti-COVID-19 Drug Discovery: A Systematic Review
por: Onyango, Okello Harrison
Publicado: (2023)

Structure-based in silico approaches for drug discovery against Mycobacterium tuberculosis
por: Kingdon, Alexander D.H., et al.
Publicado: (2021)

Consequences of exposure to pollutants on respiratory health: From genetic correlations to causal relationships
por: D’Antona, Salvatore, et al.
Publicado: (2022)

In Silico Strategies in Tuberculosis Drug Discovery
por: Macalino, Stephani Joy Y., et al.
Publicado: (2020)

Molecules against Covid-19: An in silico approach for drug development
por: Bharti, Rhythm, et al.
Publicado: (2021)

Druggability for COVID-19: in silico discovery of potential drug compounds against nucleocapsid (N) protein of SARS-CoV-2
por: Ray, Manisha, et al.
Publicado: (2020)

Naturally occurring plant-based anticancerous candidates as prospective ABCG2 inhibitors: an in silico drug discovery study
por: Ibrahim, Mahmoud A. A., et al.
Publicado: (2022)

In Silico Identification of New Targets for Diagnosis, Vaccine, and Drug Candidates against Trypanosoma cruzi
por: Trevisan, Rafael Obata, et al.
Publicado: (2020)

Modern drug discovery applications for the identification of novel candidates for COVID-19 infections
por: Rani, Isha, et al.
Publicado: (2022)

Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics
por: Gupta, Yash, et al.
Publicado: (2023)

In silico drug repurposing against SARS-CoV-2 using an integrative transcriptomic profiling approach: Hydrocortisone and Benzhydrocodone as potential drug candidates against COVID-19
por: Mirmohammadi, SeyedehMozhdeh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_infv5ngdghqk46andiqlfo2to3